ArticleJournal of nanobiotechnology2026
Mechanistic insights into mRNA-LNP interactions: role of ionizable lipid content in regulating mRNA intracellular release and translation.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Messenger RNA (mRNA) therapeutics rely on lipid nanoparticles (LNPs) for effective intracellular delivery, yet the intracellular release of mRNA from these carriers remains an underexplored barrier to translation. In this study, we investigate how the ionizable lipids within clinically relevant LNP formulations influence mRNA delivery and translation. By systematically varying the molar ratio of ionizable lipids (SM-102 and ALC-0315) while maintaining other lipid components constant, we found that LNPs containing lower ionizable lipid levels (~ 30 mol%) achieved significantly higher in vitro transfection efficiency and in vivo mRNA expression compared to standard clinical formulations (50 mol% for Moderna; 46.3 mol% for Pfizer/BioNTech). Notably, this enhancement occurred despite similar cellular uptake and endosomal escape, implicating intracellular mRNA-LNP dissociation as a previously underappreciated determinant of translational efficiency. Fluorescence colocalization analyses confirmed greater cytosolic mRNA release from LNPs with reduced ionizable lipid content. Moreover, these optimized formulations elicited stronger antigen-specific humoral and cellular immune responses in mice, highlighting their potential for improved mRNA performance. Collectively, these findings identify intracellular mRNA dissociation-rather than endosomal escape alone-as a key bottleneck in LNP-mediated delivery and demonstrate that fine-tuning ionizable lipid composition can substantially enhance mRNA performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.